Previous Section
Drug Therapy
1. Immunotherapy with dendritic cells for prostate cancer.
- Author
- Thomas-Kaskel AK; Waller CF; Schultze-Seemann W; Veelken H;
- Institution
- Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetterstrasse 55, Freiburg, Germany. anna-katharina.kaskel@uniklinik-freiburg.de
- Journal
- Int J Cancer. 2007 Aug 1;121(3):467-73.
- Abstract URL
- Click here to view abstract
2. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
- Author
- Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL;
- Institution
- Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
- Journal
- JAMA. 2008 Jul 9;300(2):173-81.
- Abstract URL
- Click here to view abstract
3. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
- Author
- Friedman J; Dunn RL; Wood D; Vaishampayan U; Wu A; Bradley D; Montie J; Sarkar FH; Shah RB; Hussain M;
- Institution
- Division of Hematology and Oncology, Department of Medicine, University of Michigan School of Medicine and University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109-0946, USA.
- Journal
- J Urol. 2008 Mar;179(3):911-5; discussion 915-6. Epub 2008 Jan 22.
- Abstract URL
- Click here to view abstract
4. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
- Author
- Shahani S; Braga-Basaria M; Basaria S;
- Institution
- Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, MD 21224, USA.
- Journal
- J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. Epub 2008 Mar 18.
- Abstract URL
- Click here to view abstract
5. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
- Author
- Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML;
- Institution
- Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
- Journal
- J Urol. 2008 May;179(5):1830-7; discussion 1837. Epub 2008 Mar 18.
- Abstract URL
- Click here to view abstract
6. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
- Author
- Higano CS;
- Institution
- University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. thigano@u.washington.edu
- Journal
- Nat Clin Pract Urol. 2008 Jan;5(1):24-34.
- Abstract URL
- Click here to view abstract
7. Monoclonal antibody therapy for prostate cancer.
- Author
- Jakobovits A;
- Institution
- Agensys Inc., 1545 17th Street, Santa Monica, CA 90404, USA. ajakobovits@agensys.com
- Journal
- Handb Exp Pharmacol. 2008;(181):237-56.
- Abstract URL
- Click here to view abstract
8. Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
- Author
- Huang X; Zhang X; Farahvash B; Olumi AF;
- Institution
- Department of Urologic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Journal
- J Urol. 2007 Nov;178(5):1846-54. Epub 2007 Sep 17.
- Abstract URL
- Click here to view abstract
9. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
- Author
- Harzstark AL; Small EJ;
- Institution
- University of California, Department of Medicine, Urologic Oncology 231, San Francisco, CA 94115, USA.
- Journal
- Expert Opin Biol Ther. 2007 Aug;7(8):1275-80.
- Abstract URL
- Click here to view abstract
10. Ketoconazole as a secondary hormonal intervention in advanced prostate cancer.
- Author
- Liebertz C; Fox P;
- Institution
- Memorial Sloan-Kettering Cancer Center, New York, NY, USA. liebertc@mskcc.org
- Journal
- Clin J Oncol Nurs. 2006 Jun;10(3):361-6.
Next: Surgical Therapy
